Patents by Inventor Brian Stephen Muehl

Brian Stephen Muehl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indole Sulfonamide Modulators of Progesterone Receptors
    Publication number: 20090069400
    Abstract: Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.
    Type: Application
    Filed: January 17, 2007
    Publication date: March 12, 2009
    Inventors: Thomas John Bleisch, Christian Alexander Clarke, Jeffrey Alan Dodge, Scott Alan Jones, Jose Eduardo Lopez, Charles Willis Lugar, III, Brian Stephen Muehl, Timothy Ivo Richardson, Ying Kwong Yee, Kuo-Long Yu
  • Triazole derivatives as tachykinin receptor antagonists
    Patent number: 7320994
    Abstract: This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: January 22, 2008
    Assignee: Eli Lilly and Company
    Inventors: Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, Erik James Hembre, Jian Eric Hong, Louis Nickolaus Jungheim, Brian Stephen Muehl, David Michael Remick, Michael Alan Robertson, Kenneth Allen Savin
  • Substituted dipeptides as growth hormone secretagogues
    Patent number: 7125840
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: October 24, 2006
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Britta Evers, Louis Nickolaus Jungheim, Brian Stephen Muehl, Gerd Ruehter, Kenneth Jeff Thrasher
  • Compounds and pharmaceutical compositions for inhibiting MRP1
    Patent number: 7101891
    Abstract: The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: September 5, 2006
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Daniel Cohen, Louis Nickolaus Jungheim, Brian Stephen Muehl, Kenneth Jeff Thrasher
  • Growth hormone secretagogues
    Patent number: 6992097
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: January 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Growth Hormone secretagogues
    Publication number: 20040122234
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Application
    Filed: June 3, 2003
    Publication date: June 24, 2004
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Compounds and pharmaceutical compositions for inhibiting mrp1
    Publication number: 20040116460
    Abstract: The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Application
    Filed: September 25, 2003
    Publication date: June 17, 2004
    Inventors: Jeffrey Daniel Cohen, Louis Nickolaus Jungheim, Brian Stephen Muehl, Kenneth Jeff Thrasher
  • Methods and compounds for inhibiting MRP1
    Patent number: 6743794
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: June 1, 2004
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst, Qiupang Wang
  • Substituted dipeptides as growth hormone secretagogues
    Publication number: 20040058971
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for usein the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Application
    Filed: March 14, 2003
    Publication date: March 25, 2004
    Inventors: Jeffrey Alan Dodge, Britta Evers, Louis Nickolaus Jungheim, Brian Stephen Muehl, Gerd Ruehter, Kenneth Jeff Thrasher
  • Growth hormone secretagogues
    Patent number: 6639076
    Abstract: This invention relates to novel compounds of formula I wherein A, B, D, E, G, J, L, X, V are as defined in the specification, and the compounds are useful in the modulation of endogenous growth hormone levels in a mammal.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: October 28, 2003
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, James Densmore Copp, William Harlan Gritton, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Methods and compounds for inhibiting mrp1
    Publication number: 20030100576
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Application
    Filed: May 21, 2002
    Publication date: May 29, 2003
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst
  • Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
    Patent number: 6258826
    Abstract: Formulations and applications thereof are described which are useful for the inhibition of various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of structure I represented by the following structure in combination with compounds of formula II represented by the following structure where X, Y, R, R′, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: July 10, 2001
    Assignee: Eli Lilly and Company
    Inventors: George Joseph Cullinan, Brian Stephen Muehl, Kenneth Jeff Thrasher
  • Benzo[B]indeno[2, 1-D]thiophene compounds, intermediates, compositions, and methods
    Patent number: 6133458
    Abstract: The invention provides benzo[b]indenothiophene compounds, intermediates, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: October 17, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Brian Stephen Muehl, Mark Alan Winter
  • Benzothiophene compounds, compositions, and methods
    Patent number: 6121293
    Abstract: The invention provides benzothiophene compounds, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions including hyperlipidemia, and estrogen-dependent cancer.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: September 19, 2000
    Assignee: Eli Lilly and Company
    Inventors: George Joseph Cullinan, Brian Stephen Muehl
  • Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
    Patent number: 6087378
    Abstract: Formulations and applications thereof are described which are useful for the inhibition of various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds represented by the following structure where X is a halogen.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: July 11, 2000
    Assignee: Eli Lilly and Company
    Inventors: George Joseph Cullinan, Brian Stephen Muehl, Kenneth Jeff Thrasher
  • Benzothiphene compounds, intermediates, compositions, and methods
    Patent number: 5985897
    Abstract: The invention provides benzothiophene compounds, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions, including hyperlipidemia, and estrogen-dependent cancer.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: November 16, 1999
    Inventors: Brian Stephen Muehl, Alan David Palkowitz
  • Naphthyl compounds and compositions, as estrogen receptor binding agents
    Patent number: 5952350
    Abstract: The invention provides a compound of formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions containing a compound of formula I, and methods of using a compound of formula I for inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions including hyperlipidemia, and estrogen dependent cancer.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: September 14, 1999
    Assignee: Eli Lilly and Company
    Inventors: George Joseph Cullinan, Brian Stephen Muehl
  • Benzo ?B! indeno ?2,1-D! thiophene compounds, intermediates, processes, compositions and methods
    Patent number: 5856341
    Abstract: The invention provides benzo?b!indenothiophene compounds of formula I ##STR1## wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6, are as defined in the specification, intermediates, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: January 5, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Brian Stephen Muehl, Mark Alan Winter
  • Benzothiophene compounds, compositions, and method
    Patent number: 5843940
    Abstract: The invention provides benzothiophene compounds, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions including hyperlipidemia, and estrogen-dependent cancer.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: December 1, 1998
    Assignee: Eli Lilly and Company
    Inventors: George Joseph Cullinan, Brian Stephen Muehl
  • Dihydrobenzo ?B! indeno ?2, 1-D! thiophene compounds, intermediates, processes, compositions and methods
    Patent number: 5834488
    Abstract: The invention provides dihydrobenzo?b!indenothiophene compounds, intermediates, processes, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: November 10, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Brian Stephen Muehl, Mark Alan Winter